Pharma News

The Council for Scientific and Industrial Research (CSIR), and Tata Medical and Diagnostics Ltd (Tata MD), the new healthcare venture from the Tata Group have teamed up to boost the COVID-19 testing capacity across Tier-II and Tier-III towns as well as rural areas, across India. The two organisations are developing capacity to handle any future surge in the COVID-19 testing requirements.

Todays approval provides an important new treatment option which can now help the millions of people in Europe living with symptomatic chronic heart failure with reduced ejection fraction said Faiez Zannad, M.D., Ph.D., EMPEROR Program clinical investigator and Emeritus Professor of Therapeutics at the University of Lorraine, France. New treatment options such as empagliflozin can save lives and help people spend less time in the hospital and more time with their families.

Council of Scientific & Industrial Research (CSIR), and Laxai Life Sciences Pvt. Ltd., Hyderabad, have been given the regulatory approval by the Drugs Controller General of India (DCGI) to undertake a two-arm phase-II clinical trial to assess the safety and efficacy of the drug Colchicine in the improvement of clinical outcomes during the treatment of COVID-19 patients.

 An alcohol-free, aqueous, non-inflammable, and non-toxic hand sanitizer has been developed by a Pune-based start-up that will soon be available in the market. It is environment friendly and gentle on the hands and has been derived from silver nanoparticles.

India Medtronic Private Limited, a wholly owned subsidiary of Medtronic plc announced the launch of Micra AV - a miniaturized, fully self-contained pacemaker that delivers advanced pacing technology to atrioventricular (AV) block patients via a minimally invasive approach. The device is the first pacemaker that can sense atrial activity without a lead or device in the upper chamber of the heart

Glenmark Pharmaceuticals Ltd, a research-led global integrated pharmaceutical company, becomes one of the first companies to launch a bioequivalent version of Tiotropium Bromide dry powder inhaler under the brand name - Tiogiva, in UK for the treatment of chronic obstructive pulmonary disease (COPD).

Strides Pharma Science Limited announced that its step‐down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore has entered into an exclusive partnership with Ennaid Therapeutics, a global pharmaceutical company to produce an oral, repurposed medication to treat mild, moderate and asymptomatic cases of COVID‐19.

Novavax, Inc announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% efficacy overall, and met the primary endpoint in its PREVENT-19 pivotal Phase 3 trial. The study enrolled 29,960 participants across 119 sites in the U.S. and Mexico to evaluate efficacy, safety and immunogenicity, with an emphasis on recruiting a representative population of communities and demographic groups most impacted by the disease.